Covid-19 booster shots take centre stage
Astra and Pfizer make the case for next-generation booster vaccines, which for the UK group at least could have important financial implications.
Biogen and the social contract
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Zolgensma flatlines, but Spinraza isn’t the beneficiary
A fiercely competitive three-horse race in spinal muscular atrophy is Evrysdi’s for the taking.
Moderna shows the value of bulk-buying
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
Astra shakes things up with Covid-19 pricing disclosure
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
How Labour’s UK generic drugs plan could have been better
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Pricing questions remain as Novo gets the nod for oral sema
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Bayer could become the latest casualty of Roche’s targeted pricing
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Pfizer shoots for a high price with tafamidis
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?